Athersys

From WikiCover

Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life.

The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation Of Gene Expression (RAGE).

Athersys is also developing MultiSte, a patented adult-derived, stem cell product platform for multiple disease indications. The company is collaborating with Angiotech Pharmaceuticals, Inc. to develop MultiStem to treat damage caused by myocardial infarction and peripheral vascular disease. The company is independently developing MultiStem for bone marrow transplantation/oncology support, ischemic stroke, and other indications.

Website: http://www.athersys.com/